Illumina Patents – Key Insights and Stats

Illumina has a total of 9281 patents globally, out of which 3896 have been granted. Of these 9281 patents, more than 78% patents are active. United States of America is where Illumina has filed the maximum number of patents, followed by Europe and Australia. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Illumina.

Illumina was founded in 1998 by Larry Bock and Anthony Czarnik. Illumina develops, manufactures and markets integrated systems for the large-scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies. As of March 2022, Illumina has a market cap of $51.84 Billion.

Do read about some of the most popular patents of Illumina which have been covered by us in this article and also you can find Illumina patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Illumina patent portfolio.

How many patents does the CEO of Illumina have?

The CEO, Francis deSouza have 0 patents.

How many patents does Illumina have?

Illumina has a total of 9281 patents globally. These patents belong to 1532 unique patent families. Out of 9281 patents, 7293 patents are active.

How many Illumina patents are Alive/Dead?

Worldwide Patents

Illumina Patents Portfolio

Patent Families

Illumina Patents

How Many Patents did Illumina File Every Year?

Illumina Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantIllumina Applications FiledIllumina Patents Granted
201120265
2012272109
2013321119
2014492137
2015636186
2016574186
20171040289
20181123351
20191326500
20201096622
2021531929
20223118

How Many Patents did Illumina File in Different Countries?

Illumina Worldwide Patents

Countries in which Illumina Filed Patents

CountryPatents
United States Of America1748
Europe838
Australia647
China563
Hong Kong (S.A.R.)485
Canada470
Japan426
Singapore365
Korea (South)363
Germany316
Israel221
India209
Brazil180
Taiwan172
New Zealand168
United Kingdom160
Russian Federation146
Denmark144
Spain134
Malaysia126
Mexico121
Austria54
Netherlands48
Philippines38
Poland37
Portugal36
South Africa30
Indonesia28
Viet Nam24
Chile24
Slovenia20
Costa Rica15
Turkey14
Lithuania14
Saudi Arabia14
Peru13
Cyprus11
Hungary10
Norway9
Switzerland8
Croatia7
Serbia6
Macao4
Argentina3
Iceland2
Eurasian Patent Organization1
United Arab Emirates1
Estonia1
San Marino1

Where are Research Centers of Illumina Patents Located?

Research Centers of Illumina Patents

10 Best Illumina Patents

US7057026B2 is the most popular patent in the Illumina portfolio. It has received 1457 citations so far from companies like Omniome Inc, 10X Genomics Inc and Raindance Technologies Inc.

Below is the list of 10 most cited patents of Illumina:

Publication NumberCitation Count
US7057026B21457
US7115400B11276
US6355431B11200
US6833246B21101
US6969488B2939
US6565727B1918
US6787308B2882
WO2005065814A1703
US6429027B1610
US20080009420A1605

Patents acquired by Illumina

Illumina has acquired 9 patents from other companies which is not associated with Illumina.

Below the table shown the patent acquisition of Illumina –

CompanyPatents Families
Cidra Corporation2
Prokaria Ltd1
BlackBerry Limited1
Quantum Biosystems Inc1
Mosaic Technologies Inc1
Conexio 4 Pty Ltd | Atria Genetics Inc1
Taiwan Semiconductor Manufacturing Company1
Powerchip Technology Corporation1

Which Companies are using Illumina Patents to Advance their Research?

If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.

The top citing companies in the Illumina patent portfolio are Bank Of America, Mastercard and Chase Bank.

List of the top forward citing Companies –

CompanyNumber of Patents
Life Technologies42
Advanced Liquid Logic Inc37
Bio-Rad Laboratories24
Ariosa Diagnostics Inc20
Natera Inc17
Agilent Technologies15
Samsung Electronics13
Sequenom11
IBM11
Qiagen Sciences Llc11

Count of 102 and 103 Type Rejections based on Illumina Patents

Top Illumina Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US7439014B238
US8613889B224
US6773566B222
US6890741B220
US9080211B218
US20120010091A116
US7741463B216
US6565727B115
US7901947B214
US8137912B214
US20100270156A114
US20080242560A113
US8241573B213
US7939021B213
US8053192B212

What Percentage of Illumina US Patent Applications were Granted?

Illumina (Excluding its subsidiaries) has filed 1283 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 768 have been granted leading to a grant rate of 78.29%.

Below are the key stats of Illumina patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Illumina?

Law FirmTotal ApplicationsSuccess Rate
Illumina Inc28385.83%
Knobbe Martens Olson & Bear Llp20579.27%
Brown Rudnick Llp5834.48%
Mrg Illumina5597.14%
The Small Patent Law Group Llc4780.85%
C O Fletcher Yoder Pc4496.55%
Weaver Austin Villeneuve & Sampson Llp3995.45%
Dierker & Kavanaugh P c380.00%
Cooley Llp296.90%
C O Haynes Beffel & Wolfeld Llp27100.00%

“We are proud to continue our tradition of driving down the cost of sequencing without compromising accuracy,” said Omead Ostadan, Senior Vice President, Marketing and Products at Illumina. “NextSeq 1000 and 2000 are designed to enable core labs, small to medium research labs and clinical facilities to access high intensity sequencing applications using our industry-leading SBS technology.”

Illumina’s NovaSeqDx platform will address growing demand for a Dx platform to support deeper sequencing at higher throughput. The company also announced the development of a regulatory-cleared version of its high-throughput NovaSequ system, with commercial availability targeted for 2022.

“At Illumina, we are focused on three key areas to scale the reach and impact of genomics—enabling breakthrough genomics research, accelerating the clinical adoption of genomics and delivering fundamentally enabling technology innovations,” said Francis deSouza, Chief Executive Officer at Illumina. “The NextSeq 1000 and 2000 Sequencing Systems, TruSight Software and our partnership with Roche, will accelerate the adoption of research and clinical sequencing for the benefit of humanity.”

EXCLUSIVE INSIGHTS COMING SOON!

What are Illumina’s key innovation segments?

What Technologies are Covered by Illumina?

The chart below distributes patents filed by Illumina in different countries on the basis of the technology protected in patents. It also represents the markets where Illumina thinks it’s important to protect particular technology inventions.

R&D Focus: How Illumina search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Illumina?

Related Articles

Terasi Ab Patents – Insights & Stats (Updated 2024)

Terasi Ab has a total of 7 patents globally, out of which 2 have been granted. Of these 7 patents, more than 85% patents are active. Sweden is where Terasi Ab has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, Sweden seems

Read More »

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.